Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Not yet recruiting 4Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 848Carcinoma, Non-Small-Cell Lung 549Neoplasms 510Prostatic Neoplasms 501Lung Neoplasms 312Colorectal Neoplasms 307Multiple Myeloma 292Neoplasm Metastasis 250Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 208Pancreatic Neoplasms 207Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 165Recurrence 162Stomach Neoplasms 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 152Glioblastoma 147Uterine Cervical Neoplasms 144Lymphoma, Non-Hodgkin 141Head and Neck Neoplasms 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 113Lymphoma, Follicular 112

Interventions

tucatinib 1tislelizumab 1disitamab vedotin 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Gastric Cancer × Clear all
NCT05586061 2025-02-07

RCTS

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
55 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Pieris Pharmaceuticals, Inc.

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡